Adult Liver Progenitor Cell Isolation for Transplantation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for liver cell transplantation are limited by the scarcity of mature human hepatocytes and the risks associated with using embryonic stem cells, which can lead to tumorigenic deviations, while adult progenitor cells are difficult to isolate and characterize due to their scarcity and complex differentiation pathways.
Innovation Solution
Isolation and characterization of adult liver-derived progenitor or stem cells that co-express mesenchymal markers like CD90, CD44, and alpha-smooth muscle actin, along with hepatocyte markers such as albumin, allowing for their expansion and differentiation into hepatocytes, reducing the risk of tumorigenicity and improving liver regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If embryonic stem cells are used for liver cell transplantation, then the supply of transplantable cells can be expanded, but the risk of tumorigenic deviations increases
Solution Approach 1:
The invention extracts and isolates specific progenitor cells (oval cells) from adult liver tissue that have the desired regenerative capacity without the tumorigenic risks of embryonic stem cells. This is achieved through specific culture conditions and marker-based identification (CK19+, CK7+, AFP+) to separate the beneficial regenerative cells from harmful potentialities.
Solution Approach 2:
The invention uses adult liver tissue, which is readily available and ethically acceptable, as a source of progenitor cells. These adult-derived cells provide sufficient transplantable material without the long-term safety concerns and ethical issues associated with embryonic stem cells, effectively replacing the need for problematic cell sources.
2Object-affected harmful factors
If adult progenitor cells are used for liver cell transplantation, then the risk of tumorigenicity is reduced, but the cells are difficult to isolate and characterize
Solution Approach 1:
The invention employs a feedback mechanism through specific culture conditions that enrich for progenitor cells based on their functional characteristics. The culture system provides feedback signals (growth factors, matrix components) that selectively promote the proliferation and maintenance of CK19+ CK7+ AFP+ progenitor cells while suppressing other cell types, enabling their isolation and characterization.
Solution Approach 2:
The invention uses immunophenotypic markers (CK19, CK7, AFP) as identifiable characteristics to detect and characterize progenitor cells. These molecular markers serve as visible identifiers that allow researchers to distinguish and isolate the desired cell population from heterogeneous liver cell suspensions through flow cytometry and immunostaining techniques.
3Reliability
If mature human hepatocytes are used for liver cell transplantation, then liver function recovery is achieved, but the supply of cells is limited
Solution Approach 1:
The invention performs preliminary expansion of progenitor cells in vitro before transplantation. Adult liver progenitor cells are isolated and cultured under specific conditions that promote their proliferation and maintenance of differentiation potential, generating sufficient cell numbers for transplantation while preserving their ability to differentiate into functional hepatocytes in vivo.
Solution Approach 2:
The invention changes the state of progenitor cells through controlled culture conditions, transforming them from a rare, undifferentiated state in adult liver to an expanded, yet still plastic, progenitor state suitable for transplantation. The culture parameters (growth factors, substrate, oxygen tension) are optimized to maintain cell potency while increasing cell quantity.
Data Source
AI summary
A method of treating liver-based inborn, metabolic deficiencies is disclosed by treatment of an individual, such as a patient suffering from liver-based inborn, metabolic deficiencies, with human progenitor or stem cells, a cell population or their progeny. The cells used in the treatment have the following characteristics. They are positive for vimentin, α-smooth muscle actin (ASMA), and for at least one mesenchymal marker such as CD90, CD29, CD73, and CD44. They are positive for at least one hepatocyte marker such as albumin, alpha-fetoprotein, alpha-1 antitrypsin, HNF-4 and MRP2 transporter. They express at least one hepatocyte-like property or function such as G6P, CYP1B1, CYP3A4, TDO, TAT, GS, GGT, CK8, and EAAT2. They are negative for at least one marker such as cytokeratin-19, CD45, CD34, CD49f, CD133, HLA-DR, and CD117. They have mesenchymal-like morphology. They originate from human adult liver cells.